Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.47 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685223 | 0.88 | ADORA1 (0.58) | ADORA1ADORA2AADORA3ADORA2BRNASEL | |
| SCHEMBL31685258 | 0.86 | ADORA1 (0.52) | ADORA1ADORA2AADORA2BRNASELIMPDH2 | |
| SCHEMBL31685735 | 0.86 | ADORA1 (0.52) | ADORA1ADORA2AADORA3ADORA2BRNASEL | |
| SCHEMBL31685809 | 0.85 | ADORA3 (0.62) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL31685480 | 0.85 | IMPDH2 (0.63) | ADORA1RNASELTAS1R3TAS1R1IMPDH2 | |
| SCHEMBL31685778 | 0.84 | ADORA3 (0.52) | ADORA1ADORA2AADORA3ADORA2B | |
| SCHEMBL31685287 | 0.83 | ADORA1 (0.52) | ADORA1TAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL31685227 | 0.83 | TAS1R3 (0.62) | ADORA1TAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL31685641 | 0.83 | ADORA1 (0.61) | ADORA1ADORA2AADORA2BRNASELCA5A | |
| SCHEMBL31685602 | 0.82 | ADORA1 (0.49) | ADORA1ADORA3RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | ADORA1 935/4885ADORA2A 593/4885ADORA3 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.